Tenapanor
- Generic Name
- Tenapanor
- Brand Names
- Ibsrela
- Drug Type
- Small Molecule
- Chemical Formula
- C50H66Cl4N8O10S2
- CAS Number
- 1234423-95-0
- Unique Ingredient Identifier
- WYD79216A6
- Background
Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class and therefore exists as a novel alternative in the treatment of IBS-C. In October 2023, tenapanor was approved for the treatment of chronic kidney disease.
- Indication
Tenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults.
It is also indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Associated Conditions
- Chronic Kidney Disease (CKD), Irritable Bowel Syndrome With Constipation (IBS-C)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.